Proteome Sciences (PRM) Share Price, News & Analysis

Company Overview

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also provides top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

Key Stats

• Today's Range: 2.63 to 3.48
• 50-Day Range: 2.61 to 3.78
• 52-Week Range: 2.22 to 5.40
• Volume: 265,308 shs
• Average Volume: 211,804 shs
• Market Capitalization: £7.75 million
• P/E Ratio: N/A
• Dividend Yield: 6.17%
• Price Target: N/A
• Consensus Rating: N/A

PRM Stock Analysis - Frequently Asked Questions

How have PRM shares performed this year?

Proteome Sciences' stock was trading at GBX 3.40 at the beginning of the year. Since then, PRM shares have decreased by 22.8% and is now trading at GBX 2.63.

How were Proteome Sciences' earnings last quarter?

Proteome Sciences plc (LON:PRM) announced its quarterly earnings data on Thursday, April, 10th. The company reported ($1.15) EPS for the quarter. Proteome Sciences had a negative net margin of 0.04% and a negative trailing twelve-month return on equity of 0.01%.

How do I buy shares of Proteome Sciences?

Shares of PRM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Proteome Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Proteome Sciences investors own include Lloyds Banking Group (LLOY), Petrofac (PFC), ValiRx (VAL), boohoo group (BOO), Intel (INTC), Mondi (MNDI) and Taiwan Semiconductor Manufacturing (TSM).

Company Calendar

• Last Earnings: 4/10/2025
• Today: 7/25/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: Chemicals
• Current Symbol: LON:PRM
• CIK: N/A
• Web: www.proteomics.com
• Phone: +44-20-70432116
• Fax: N/A
• Employees: 240
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (1.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£4.08 million
• Net Margins: -0.04%
• Pretax Margin: N/A
• Return on Equity: -0.01%
• Return on Assets: -19.25%

Debt

• Debt-to-Equity Ratio: -258.66
• Current Ratio: 0.20
• Quick Ratio: 0.37

Sales & Book Value

• Annual Sales: £10.88 billion
• Price / Sales: 0.00
• Cash Flow: GBX 0.70 per share
• Price / Cash Flow: 3.73
• Book Value: GBX (1.78) per share
• Price / Book: -1.47

Miscellaneous

• Outstanding Shares: 295,167,274
• Free Float: N/A
• Market Cap: £7.75 million
• Optionable: Not Optionable
• Beta: 0.07